Human and mouse adipose-derived cells support feeder-independent induction of pluripotent stem cells

Sugii, Shigeki; Kida, Yasuyuki S.; Kawamura, Teruhisa; Suzuki, Jotaro; Vassena, Rita; Yin, Yunqiang; Lutz, Margaret; Berggren, W. Travis; Belmonte, Juan C. I.; Evans, Ronald M.

doi:10.1073/pnas.0910172106

Cited by 157 publications

(111 citation statements)

References 26 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…In vitro differentiation of the iPSCs into three germ layers was induced as described (50,51). Embryoid bodies (EBs), formed by partially dissociating iPSCs using collagenase type IV (Invitrogen), were transferred to ultralow attachment plates (Corning) and cultured in DMEM/F12 (1:1) medium supplemented with 20% knockout serum (Invitrogen), 4.5 g/L L-glutamine, 1% nonessential amino acids, 0.1 mM 2-mercaptoethanol, and 5% FBS.…”

Section: Methodsmentioning

confidence: 99%

Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs

Park

Kim

Kweon

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

124

View full text Add to dashboard Cite

Significance Hemophilia A, a genetic bleeding disorder, is often caused by chromosomal inversions that involve a portion of the blood coagulation factor VIII ( F8 ) gene that encodes one of the key enzymes in blood clotting. In this study, we developed enzymes known as transcription activator-like effector nucleases (TALENs) that cleave chromosomal DNA in a targeted manner to invert the 140-kbp chromosomal segment that spans the portion of the F8 gene in human induced pluripotent stem cells (iPSCs) to create a hemophilia A model cell line. In addition, we reverted the inverted segment back to its normal orientation using the same enzymes. This strategy provides an iPSC-based novel therapeutic option for the treatment of hemophilia A.

show abstract

Section: Methodsmentioning

confidence: 99%

Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs

Park

Kim

Kweon

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

124

View full text Add to dashboard Cite

show abstract

“…Adiposederived stromal cells (ASCs), which are another type of MSCs, also have the ability to serve as feeder cells for human ESCs/iPSCs [46,47]. Sugii et al [58] showed that ASCs express high levels of bFGF, TGFβ, fibronectin, and vitronectin and can thus serve as feeder cells for both autologous and heterologous human iPSCs. Because ASCs can be easily isolated by surgery or lipoaspiration from adults, their use as feeder cells is expected to provide an important step toward establishing safe, clinical-grade human iPSC lines.…”

Section: Human-derived Feeder Cellsmentioning

confidence: 99%

Feeder Cell Sources and Feeder-Free Methods for Human iPS Cell Culture

Kamano

Wang

et al. 2015

Interface Oral Health Science 2014

View full text Add to dashboard Cite

Induced pluripotent stem cells (iPSCs) hold great promise for regenerative medicine and disease modeling. The original methods to grow human iPSCs utilized methods developed for human embryonic cells (ESCs), in which mitotically inactivated mouse-derived fibroblasts are mainly used as a "feeder" cell layer to maintain the undifferentiated status of pluripotent stem cells. However, these methods still require further consideration to facilitate cell expansion and to maintain the undifferentiated state of human iPSCs and/or ESCs for a longer period of time. In addition, the use of animal-derived feeders should be avoided for eventual clinical application of iPSC therapies. Therefore, human-derived feeder culture systems or feeder-free culture systems are currently being developed to prevent exposure to animal pathogens. In this review, existing mouse and human feeder culture systems for human ESCs and iPSCs are first introduced, and then previously reported feeder-free culture methods using extracellular matrixassociated products or synthetic biomaterials are outlined to discuss an appropriate culture system for clinical application of iPSCs.

show abstract

“…Besides the virus-free integration-free reprogramming methods, conditions for mouse feeder-free iPSC culture are being constantly improved to make iPSCs safer and more suitable for clinical applications [37][38][39][40][41]. However, it is still a challenge to establish systems that can sufficiently support human iPSC self-renewal, genetic modifications and differentiation while compatible with clinical production under current Good Manufacturing Practice (cGMP) standards.…”

Section: Clinical Grade Ipsc Generation and Differentiationmentioning

confidence: 99%

Promise and challenges of human iPSC-based hematologic disease modeling and treatment

Chou

Cheng

2012

Int J Hematol

View full text Add to dashboard Cite

Postnatal hematopoietic stem cells (HSCs) from umbilical cord blood and adult marrow/blood have been successfully used for treating various human diseases in the past several decades. However, the availability of optimal numbers of HSCs from autologous patients or allogeneic donors with adequate match remains a great barrier to improve and extend HSC and marrow transplantation to more needing patients. In addition, the inability to expand functional human HSCs to sufficient quantity in the laboratory has hindered our research and understanding of human HSCs and hematopoiesis. Recent development in reprogramming technology has provided patient-specific pluripotent stem cells (iPSCs) as a powerful enabling tool for modeling disease and developing therapeutics. Studies have demonstrated the potential of human iPSCs, which can be expanded exponentially and amenable for genome engineering, for using in modeling both inherited and acquired blood diseases. Proof-of-principle studies have also shown the feasibility of iPSCs in gene and cell therapy. Here, we review the recent development in iPSC-based blood disease modeling, and discuss the unsolved issues and challenges in this new and promising field.

show abstract

Human and mouse adipose-derived cells support feeder-independent induction of pluripotent stem cells

Cited by 157 publications

References 26 publications

Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs

Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs

Feeder Cell Sources and Feeder-Free Methods for Human iPS Cell Culture

Promise and challenges of human iPSC-based hematologic disease modeling and treatment

Contact Info

Product

Resources

About